ALLMedicine™ Anaplastic Thyroid Carcinoma Center
Research & Reviews 301 results
https://doi.org/10.1002/dc.25028
Diagnostic Cytopathology; Bantumilli S, Zhu LC et. al.
Aug 6th, 2022 - Anaplastic thyroid carcinoma is an infrequent, but aggressive fatal subtype of thyroid cancer. The osteoclastic variant of anaplastic carcinoma is a rare subtype of anaplastic carcinoma with rare cases reported in the literature. Molecular targete...
https://doi.org/10.1530/EJE-22-0366
European Journal of Endocrinology; Buffet C, Allard L et. al.
Jul 29th, 2022 - Recently, targeted therapies using BRAFV600E and MEK inhibitors (dabrafenib and trametinib, respectively) have been recommended in BRAF-mutated anaplastic thyroid carcinoma (ATC). Considering the fast development of ATC, droplet digital PCR (ddPCR...
https://doi.org/10.1007/s12020-022-03146-0
Endocrine Pizzimenti C, Fiorentino V et. al.
Jul 22nd, 2022 - The incidence of thyroid carcinoma has increased globally in the past years. Papillary thyroid carcinoma (PTC) is the most frequent neoplasm of the thyroid gland comprehending the 90% of the thyroid carcinoma and has an indolent clinical behaviour...
https://clinicaltrials.gov/ct2/show/NCT03181100
Jul 15th, 2022 - PRIMARY OBJECTIVE: I. To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). SECONDARY OBJECTIVES: I. To evaluate the safety and efficacy (Resp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261050
BMC Cancer; Czajkowski M, Kaemmerer D et. al.
Jul 8th, 2022 - Papillary and follicular thyroid carcinomas can be treated surgically and with radioiodine therapy, whereas therapeutic options for advanced stage IV medullary and for anaplastic tumours are limited. Recently, somatostatin receptors (SSTs) and the...
Guidelines 3 results
https://doi.org/10.1507/endocrj.EJ20-0025
Endocrine Journal; Ito Y, Onoda N et. al.
Apr 10th, 2020 - The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the ther...
https://doi.org/10.6004/jnccn.2018.0089
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Nasr C et. al.
Dec 14th, 2018 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.
Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...
Clinicaltrials.gov 5 results
https://clinicaltrials.gov/ct2/show/NCT03181100
Jul 15th, 2022 - PRIMARY OBJECTIVE: I. To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). SECONDARY OBJECTIVES: I. To evaluate the safety and efficacy (Resp...
https://clinicaltrials.gov/ct2/show/NCT04592484
May 20th, 2022 - This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed despite receiving...
https://clinicaltrials.gov/ct2/show/NCT02114658
Aug 3rd, 2017 - The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).
https://clinicaltrials.gov/ct2/show/NCT00507429
Jun 9th, 2014 - Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for...
https://clinicaltrials.gov/ct2/show/NCT00115739
Apr 21st, 2014 - Anaplastic thyroid carcinomas (ATC) are high grade neoplasms, which account for approximately 2% to 5% of primary malignant thyroid tumors but more than 50% of thyroid cancer deaths. Because therapies for anaplastic thyroid carcinoma are very limi...
News 13 results
https://www.onclive.com/view/running-a-lot-of-discipline-and-a-little-bit-of-jazz-walter-j-curran-jr-is-a-giant-of-cancer-care-in-radiation-oncology
Apr 6th, 2022 - Walter J. Curran Jr, MD, started a new job this year working for an Australia-based oncology services provider, so it’s no surprise that he spent the summer with his mind and his device screens tethered to the other side of the world. Then again,...
https://www.onclive.com/view/next-generation-braf-inhibitor-cobicistat-elicits-encouraging-activity-in-braf-refractory-solid-tumors
Oct 6th, 2021 - PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat (Tybost) was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors, according to result...
https://www.onclive.com/view/advanced-hcc-whats-next
Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...
https://www.onclive.com/view/priority-review-designation-in-tgct-bla-submitted-in-her2-breast-cancer-and-more
Apr 2nd, 2021 - Today- A priority review designation in tenosynovial giant cell tumor, a biologic license application submitted in HER2-positive breast cancer, a recommendation in renal cell carcinoma, encouraging findings in prostate cancer and multiple myelo...
https://www.staging.medscape.com/viewarticle/936044
Aug 21st, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...